Cardiff Oncology shares plunge after Q2 earnings miss
On Wednesday, BTIG confirmed its positive stance on Zoetis Inc . (NYSE:ZTS), maintaining a Buy rating and a $200.00 price target for the company’s shares. The affirmation follows Zoetis’ strong performance in the first quarter, where the company surpassed expectations and revised its future earnings forecast upward. Zoetis reported a 9% year-over-year operational organic revenue growth and an 8% increase in adjusted earnings per share (EPS). According to InvestingPro data, the company maintains a GREAT financial health score, though it currently trades at a relatively high P/E ratio of 29x.
Zoetis’ U.S. companion animal business saw an 8% year-over-year growth, while on a global scale, the operational growth stood at 9%. This robust expansion was propelled by significant gains across several product lines. The Simparica franchise led with a 19% year-over-year growth, followed by the OA pain franchise, including Librela and Solensia, which grew by 15%. Furthermore, the key dermatology franchise, featuring Apoquel and Cytopoint, experienced a 10% year-over-year increase. With an impressive gross profit margin of 71% and consistent dividend growth for 12 consecutive years, as highlighted by InvestingPro, Zoetis demonstrates strong operational efficiency.
Despite the slower-than-expected adoption of OA pain treatments, Zoetis has still managed to achieve double-digit growth in this segment. BTIG’s analyst highlighted the company’s potential for further global market penetration with key products like Librela, Solensia, Simparica Trio, and Apoquel. The analyst’s outlook suggests confidence in Zoetis’ ability to sustain solid growth moving forward.
Zoetis’ strong quarterly performance and the optimistic projections by BTIG underpin the firm’s decision to reiterate their Buy rating and $200 price target on Zoetis shares. The company’s strategic positioning and the successful expansion of its product franchises appear to set the stage for continued growth in the animal health sector.
In other recent news, Zoetis Inc. reported a strong financial performance for the first quarter of 2025, surpassing analysts’ expectations with earnings per share (EPS) of $1.48 against a forecast of $1.41. The company also exceeded revenue expectations, reporting $2.22 billion compared to the anticipated $2.20 billion. Despite this positive outcome, analysts from UBS and Leerink Partners have adjusted their price targets for Zoetis, with UBS lowering it to $170 and Leerink to $180, citing mixed sales performance and macroeconomic pressures. UBS maintained a Neutral rating, while Leerink continued to rate the stock as Outperform, expressing optimism for Zoetis’ prospects in 2025 and 2026. Sales of Zoetis’ Librela and Cytopoint products did not meet expectations, with weather conditions affecting sales of the latter. The company also faces potential risks from a 25% tariff duty rate on pharmaceutical imports into the U.S. Zoetis remains confident in its ability to navigate these challenges, maintaining its full-year revenue guidance of $9.425 to $9.575 billion and projecting an adjusted net income of $2.775 to $2.825 billion for the year.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.